Nuclear Medicine Market Business Strategy Insights

The global Nuclear Medicine Market was valued at USD 21.3 billion in 2025 and is projected to grow from USD 24.1 billion in 2026 to USD 38.2 billion by 2033, expanding at a CAGR of 6.8% from 2026 to 2033. North America dominated the market with the largest revenue share of 42.8% in 2025, supported by advanced healthcare infrastructure, favorable reimbursement policies, and increasing investments in radiopharmaceutical research. The market is experiencing sustained growth due to the expanding use of precision diagnostics and targeted radionuclide therapies for cancer, cardiovascular disorders, neurological diseases, and other chronic conditions. Nuclear medicine combines molecular imaging with targeted therapeutic approaches, enabling clinicians to diagnose diseases at earlier stages and deliver personalized treatment while minimizing damage to surrounding healthy tissues. As healthcare systems increasingly shift toward precision medicine and value-based care, nuclear medicine continues to gain importance in modern clinical practice. The rising global burden of cancer remains one of the primary growth drivers for the industry. According to the World Health Organization (WHO), approximately 20 million new cancer cases and 9.7 million cancer-related deaths were recorded worldwide in 2022, while nearly 53.5 million people were living within five years of a cancer diagnosis. Nuclear medicine plays a critical role in oncology by enabling highly targeted imaging and radioligand therapies that deliver radioactive isotopes directly to cancer cells, improving treatment precision while reducing systemic toxicity and adverse side effects. The increasing prevalence of prostate cancer, neuroendocrine tumors, lymphoma, and metastatic cancers is expected to further accelerate demand for advanced nuclear medicine procedures. Rapid advancements in radiopharmaceutical development are also reshaping the competitive landscape. A robust clinical pipeline featuring products such as Betalutin, Yttrium-90 microspheres, PNT2003, and 177Lu-PNT2002 highlights the industry's strong innovation momentum. In December 2023, Lantheus Holdings, Inc. and POINT Biopharma Global Inc. announced positive topline results from the pivotal Phase 3 SPLASH study, evaluating 177Lu-PNT2002, a PSMA-targeted radioligand therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Such advancements are strengthening confidence in targeted radiopharmaceutical therapies and encouraging greater investment across pharmaceutical and biotechnology sectors. Download a free sample copy of the Nuclear Medicine Market report to understand detailed coverage and inclusions in the final report Technological innovation is further transforming nuclear medicine through the integration of advanced imaging systems such as Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), hybrid PET/CT, PET/MRI platforms, AI-assisted image reconstruction, and quantitative imaging analytics. These technologies improve diagnostic accuracy, reduce scan times, optimize radiation doses, and enhance workflow efficiency. Artificial intelligence is also emerging as a valuable tool for image interpretation, lesion detection, workflow automation, and treatment planning, supporting broader adoption of nuclear medicine across healthcare systems. Government initiatives and favorable reimbursement policies continue to strengthen market expansion. In the United States, the Centers for Medicare & Medicaid Services (CMS) introduced an additional reimbursement for Tc-99m produced from non-highly enriched uranium (HEU), encouraging wider adoption of safer radiopharmaceutical production methods while improving patient access to essential diagnostic imaging procedures. Similar investments in domestic radioisotope production, nuclear reactor modernization, and supply chain resilience are expected to support long-term market stability as global demand for medical isotopes c...